TTOO Stock Overview
An in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
T2 Biosystems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.061 |
| 52 Week High | US$6.80 |
| 52 Week Low | US$0.056 |
| Beta | 0.34 |
| 1 Month Change | -76.52% |
| 3 Month Change | -88.03% |
| 1 Year Change | -98.88% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price
Apr 18
T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease
Oct 13T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M
Sep 29T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement
Sep 22T2 Biosystems' Survival Riddle
Aug 26T2 Biosystems Q2 2022 Earnings Preview
Aug 12Shareholder Returns
| TTOO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -70.9% | 0.4% | 1.5% |
| 1Y | -98.9% | -2.7% | 22.4% |
Return vs Industry: TTOO underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: TTOO underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| TTOO volatility | |
|---|---|
| TTOO Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TTOO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TTOO's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 113 | John Sperzel | www.t2biosystems.com |
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens.
T2 Biosystems, Inc. Fundamentals Summary
| TTOO fundamental statistics | |
|---|---|
| Market cap | US$1.28m |
| Earnings (TTM) | -US$42.95m |
| Revenue (TTM) | US$7.68m |
0.2x
P/S Ratio0.0x
P/E RatioIs TTOO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTOO income statement (TTM) | |
|---|---|
| Revenue | US$7.68m |
| Cost of Revenue | US$26.70m |
| Gross Profit | -US$19.03m |
| Other Expenses | US$23.93m |
| Earnings | -US$42.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | -247.83% |
| Net Profit Margin | -559.52% |
| Debt/Equity Ratio | -101.8% |
How did TTOO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:20 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
T2 Biosystems, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Karen Koski | BTIG |
| Kyle Mikson | Canaccord Genuity |